key: cord-0995598-z53zbngu
authors: Tang, Wen-Fang; Tsai, Hui-Ping; Chang, Yu-Hsiu; Chang, Tein-Yao; Hsieh, Chung-Fan; Lin, Chia-Yi; Lin, Guan-Hua; Chen, Yu-Li; Jheng, Jia-Rong; Liu, Ping-Cheng; Yang, Chuen-Mi; Chin, Yuan-Fan; Chen, Cheng Cheung; Kau, Jyh-Hwa; Hung, Yi-Jen; Hsieh, Po-Shiuan; Horng, Jim-Tong
title: Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation
date: 2021-01-28
journal: Biomed J
DOI: 10.1016/j.bj.2021.01.005
sha: 41f1da6d7bec852bb8b7ea664b4fcc4dd383a19b
doc_id: 995598
cord_uid: z53zbngu

BACKGROUND: s: While severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection presents with mild or no symptoms in most cases, a significant number of patients become critically ill. Remdesivir has been approved for the treatment of coronavirus disease 2019 (COVID-19) in several countries, but its use as monotherapy has not substantially lowered mortality rates. Because agents from traditional Chinese medicine (TCM) have been successfully utilized to treat pandemic and endemic diseases, we designed the current study to identify novel anti-SARS-CoV-2 agents from TCM. MATERIALS AND METHODS: We initially used an antivirus-induced cell death assay to screen a panel of herbal extracts. The inhibition of the viral infection step was investigated through a time-of-drug-addition assay, whereas a plaque reduction assay was carried out to validate the antiviral activity. Direct interaction of the candidate TCM compound with viral particles was assessed using a viral inactivation assay. Finally, the potential synergistic efficacy of remdesivir and the TCM compound was examined with a combination assay. RESULTS: The herbal medicine Perilla leaf extract (PLE, approval number 022427 issued by the Department of Health and Welfare of Taiwan) had EC(50) of 0.12 ± 0.06 mg/mL against SARS-CoV-2 in Vero E6 cells – with a selectivity index of 40.65. Non-cytotoxic PLE concentrations were capable of blocking viral RNA and protein synthesis. In addition, they significantly decreased virus-induced cytokine release and viral protein/RNA levels in the human lung epithelial cell line Calu-3. PLE inhibited viral replication by inactivating the virion and showed additive-to-synergistic efficacy against SARS-CoV-2 when used in combination with remdesivir. CONCLUSIONS: Our results demonstrate for the first time that PLE is capable of inhibiting SARS-CoV-2 replication by inactivating the virion. Our data may prompt additional investigation on the clinical usefulness of PLE for preventing or treating COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) [1] . SARS-CoV-2 is a positive-sense, single-stranded RNA virus containing a canonical set of four major structural proteins. These include the spike (S), membrane (M), and envelope (E) proteins localized to the membrane envelope and the nucleocapsid (N) protein found in the ribonucleoprotein core. Similar to the SARS-CoV that caused a disease outbreak in 2003, SARS-CoV-2 uses its spike protein to interact with its cellular receptor, angiotensin-converting enzyme 2, for host cell entry [2, 3] . Four other human coronaviruses (HCoVs) are typical causative agents of common colds. These include HCoV-OC43 and HCoV-229E that are responsible for ≤ 30% of all upper respiratory tract infections [4] . While SARS-CoV-2 infection presents with mild to no symptoms in most cases, a significant number of patients become critically ill and require hospitalization and intensive care. As of October 28, 2020, there were >44 million confirmed cases of COVID-19 and 1,172,000 COVID-19-related deaths worldwide. Notably, SARS-CoV-2 infections can elicit cytokine storms characterized by massively increased plasma concentrations of inflammatory cytokines and chemokines (i.e., IL-6, IFN-γ, TNF-α, MCP1, and CXCL10) [5] [6] [7] [8] .

While vaccination programs against SARS-CoV-2 are currently ongoing, the long-term safety of available vaccines remains a major concern. In this scenario, there is an urgent need for J o u r n a l P r e -p r o o f both repurposed drugs and agents from traditional Chinese medicine (TCM) to contain the spread of this highly contagious disease.

The repurposed antiviral remdesivir -which was originally developed and administered as an Ebola polymerase inhibitor -is currently the only antiviral approved for COVID-19 therapy.

While it reduces hospitalization length, it does not significantly lower COVID-19 mortality rates [9] . Agents from TCM have been frequently prescribed to prevent or treat the SARS-CoV outbreak in 2003. Medication records from antiquity disclosed that certain TCMs can be clinically useful to treat respiratory infections. In previous SARS-CoV outbreaks, several provinces in China issued TCM programs based on the principles tonifying qi, protecting against external pathogens, dispersing wind, discharging heat, and resolving dampness. The most frequently used herbs -prescribed either separately or in combination - Perilla (Perilla frutescens L. Britt) is commonly known as perilla, Korean perilla, beefsteak plant, purple mint, perilla mint, Chinese basil, Zisu (in China), and Shiso (in Japan). Various parts of the perilla plant have different ethnopharmacological effects. While the leaves are used to tonify stomach function, discharge heat, and improve healthy qi, seeds decrease qi, resolve phlegm, relieve cough and asthma, and alleviate constipation [10] . In the current study, we investigated the mechanisms underlying the anti-SARS-CoV-2 activity of perilla leaf extract (PLE) using standardized herbal preparations and identified PLE as a virucidal agent that directly inactivates the viral particle.

J o u r n a l P r e -p r o o f

Vero E6, human hepatocellular carcinoma (Huh7), human rhabdomyosarcoma (RD), and Calu-3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco, BRL, Gaithersburg, MD, USA) supplemented with 10% (w/v) fetal bovine serum (FBS).

Madin-Darby canine kidney (MDCK) cells were cultured in DMEM containing 10% FBS, 2 mM L-glutamine (Gibco), 0.1 mM nonessential amino acid mixture (Gibco), 100 U/mL penicillin, and 0.1 mg/mL streptomycin (Gibco). Cell lines were obtained from the Chang Gung Memorial Hospital and passages were < 25 in all cases. The SARS-CoV-2 strain CDC-4 (CGMH-CGU-01; GISAID accession number EPI_ISL_411915 and NCBI accession number MT192759) was provided by the Taiwan Center for Disease Control [11] and amplified in Vero E6 cells. HCoV-229 was obtained from the Research Center for Emerging Viral Infections of the Chang Gung University (Kweishan, Taoyuan, Taiwan) and amplified in Huh7 cells. The viral titer was determined by a plaque assay. SARS-CoV-2 was handled either in a biosafety level three or a biosafety level four laboratory. Figure S1 . The chromatograms detected the presence of rosmarinic acid -which serves as the constituent marker of PLE according to government guidelines.

A 96-well tissue culture plate was seeded with Vero E6 cells (2 × 10 4 /well) and incubated at 37 o C for 16-20 h under 5% CO 2 . Cell viability was measured following incubation with PLE for 72 h and subsequent staining with 5 mg/mL methyl thiazolyl tetrazolium (MTT).

Thereafter, the crystal product formazan was dissolved in dimethyl sulfoxide (200 µL/well), and the absorbance (OD 570nm ) of each well was measured using a microplate reader. CC 50 represents the cytotoxicity concentration at which 50% cell death occurs [12] . Live imaging of virus-induced CPE was recorded using CytoSMART Lux2 (Scintica Instrumentation Inc., Maastricht, the Netherlands). 

Total RNA from Vero E6 or Calu-3 cells was extracted using TRIzol reagent (Thermo Fisher Scientific Inc, MA, USA) according to the manufacturer's instructions. Equal amounts of total RNA were reverse transcribed using the M-MLV reverse transcriptase system (Thermo Fisher Scientific Inc.) using random primers. Subsequently, qRT-PCR was performed with a QuantStudio3 RT-qPCR system (Applied Biosystems, Foster City, CA, USA) using primer pairs specific for the E gene. GAPDH was used as the internal control. The primer sequences J o u r n a l P r e -p r o o f are listed in Table S1 , and the relative mRNA expression was calculated using the 2 − △△ Ct method [13] .

Cells were harvested, treated with 3× sodium dodecyl sulfate (SDS) sample buffer, denatured at 37 o C for 1 h, and subjected to 8% SDS-polyacrylamide gel electrophoresis. Proteins were immunoblotted onto polyvinylidene fluoride membranes and stained with mouse monoclonal anti-spike (GTX632604; GeneTex, Hsinchu, Taiwan, 1: 5000) or mouse monoclonal anti-nucleocapsid (GTX632269, GeneTex, 1: 2000) antibodies. Mouse monoclonal GAPDH (GTX627408, GeneTex, 1: 5000) was used as the loading control.

The virus (3,000 PFUs) was incubated with increasing PLE concentrations in 500 µL DMEM for 30 min at 37 °C and 5% CO 2 . The reaction mixture was diluted 100-fold to reduce the antiviral effect of PLE. After treatment, the residual viral titer was measured using a plaque assay.

Calu-3 cells (5 × 10 5 /well) were seeded in six-well plates for 3-4 days before infection with SARS-CoV-2 (MOI = 0.01) for 1 h. The virus was subsequently removed and replaced with E 2 .

At 48 h p.i., cells were harvested for qRT-PCR and western blot analyses. The cytokine primer sequences are shown in Table S1 .

Calu-3 cells (5 × 10 5 /well) were seeded on a coverslip glass, which was set in a six-well plate.

After infection with SARS-CoV-2 at a MOI of 0.01, cells were fixed with PFA at 48 h p.i. and stained with anti-spike antibodies (GeneTex). Fluorescence was examined using a confocal microscope (LSM780, Carl Zeiss AG, Oberkochen, Germany).

Vero E6 cells were seeded in a six-well tissue culture plate. Several dilutions of both remdesivir (concentrations: 0, 2, and 4 µM) and PLE (concentrations: 0, 1.25, and 2.5 mg/mL) were subsequently tested in a checkerboard matrix. None of the tested combinations was found to induce cytotoxicity. The inhibitory efficacy was assessed by qRT-PCR at 24 h p.i. To evaluate drug-drug interactions, the combination index was calculated by using Highest Single Agent (HSA) reference model of Synergy Finder, version 2.0 [14] . Interactions between drugs were considered antagonistic, additive, or synergistic when the combination indices were < -10, -10 ≤ × ≤ 10, or > 10, respectively.

Data were analyzed using GraphPad Prism v. 8.0 (GraphPad Software, La Jolla, CA, USA) and presented as means ± standard error of the mean. Differences between pairs of means were analyzed using two-sample t-test. All tests were two-sided and P value less than 0.05 was considered statistically significant.

To identify herbal extracts with potential activity against SARS-CoV-2, we performed a primary antiviral screen of a panel of Chinese herbs known to eliminate dampness and reduce heat. To this end, an assay of these materials was carried out to measure the inhibition of virus-induced cell death (Table 1) . PLE had an EC 50 of 0.12 ± 0.06 mg/mL, a CC 50 of 4.64 0.16 mg/mL, and a selectivity index of ~40.65 for SARS-CoV-2 inhibition in Vero E6 cells (Table 2) . PLE was also capable of inhibiting EV-A71 and influenza virus -suggesting a broad-spectrum inhibition capacity against RNA viruses. The antiviral activity was apparently highly specific -inasmuch as no HCoV-229E inhibition was evident at a PLE concentration of ≤ 1.25 mg/mL (Table 1) 

We assessed the time course of drug addition to identify the stage at which PLE inhibits the viral replication cycle ( Figure 1A) . Compared with the mock-treated control, the addition of PLE markedly inhibited viral RNA and protein syntheses at treatment course from -3 h p.i. to 24 h p.i. (lanes 2; Figures 1B-1C ). PLE showed a stronger inhibitory activity when it was added at earlier time points (from -3 h to 0 h p.i. and from -1 h to 0 h p.i.) than when it was added between 0 h p.i. and 24 h p.i. (Figures 1B-1C) . These findings indicate that PLE may play a role in blocking viral entry. PLE treatment inhibited SARS-CoV-2 plaque formation in a dose-dependent manner ( Figure 1D ). In addition, we found that the antiviral activity of PLE (1.25 mg/mL) was similar to that of remdesivir (10 µM; positive control) as shown by the extent of inhibition of plaque formation ( Figure 1D ). The foregoing data strongly support the anti-SARS-CoV-2 activity of PLE.

The primary targets of SARS-CoV-2 are the epithelial cells in the airways and lungs. Therefore, the antiviral efficiency of PLE was assessed in the human lung alveolar cell line Calu-3, which is highly susceptible to viral infection [15] . As expected, SARS-CoV-2 infection was robust in Calu-3 cells. Viral RNA and protein syntheses were markedly increased by 48 h p.i. but were inhibited by both remdesivir and PLE in a dose-dependent manner (Figures 2A-2B Figure 2C ). Relative cytokine/chemokine mRNA levels were increased several fold upon viral infection ( Figure 2C ). Similar to remdesivir, 1.25 mg/mL PLE significantly decreased the relative cytokine/chemokine mRNA levels. The viral protein/RNA synthesis was highly positively correlated with cytokine levels, indicating that cytokine inhibition is closely associated with PLE-mediated reduction in viral replication (Figures 2A-2C) .

We observed that PLE inhibited the initial step of viral replication in a time-of-addition assay ( Figure 1) . We thus performed a viral inactivation assay to determine whether PLE can directly target the virion. Viruses subjected to PLE treatment showed significant dose-dependent decrease in their relative titers. Thus, PLE directly targets the virus and has virucidal efficacy ( Figure 3A ). We used immunofluorescence staining to evaluate the reduction in viral protein synthesis in infected cells treated with PLE ( Figures 3B-3C ). Figure   3B (bright field) shows Calu-3 cells clustered in a characteristic multinuclear structure. The immunofluorescence foci of the viral spike protein were evenly distributed in the cytoplasm at the site of viral replication. As shown in Figure 3C 

While remdesivir does not reduce COVID-19-related mortality, clinical trials have shown improvements in terms of recovery time. Hence, it is necessary to combine this drug with other therapeutic agents characterized by different modes of action. We assessed drug-drug interactions between PLE and remdesivir using a cell-based assay. We used qRT-PCR to evaluate the inhibition of viral RNA synthesis by drug combinations ( Figure 4A ). The results of data analysis obtained using SynergyFinder version 2 are presented in Figure 4B . The combination of PLE and remdesivir had a synergistic score of 14.98 ± 5.84, indicating an additive-to-synergistic effect of PLE when combined with remdesivir ( Figure 4B ). We also used MTT staining to evaluate the inhibition efficacy on cell viability by drug combinations ( Figure S3) . A similar additive-to-synergistic effect was evident (synergistic score: 10.06 ± 3.76). Taken together, these results provide a strong rationale for clinical trials investigating the potential utility of combinatory PLE and remdesivir treatment. production. Viral entry inhibitors offer several therapeutic advantages. Accordingly, they may directly attenuate or destroy the virus and can be relatively less cytotoxic than agents with other mechanisms of action as they need not permeate the host cell. In addition, they may also display a potential prophylactic efficacy. Intriguingly, PLE can be formulated not only into agonists but also as external preparations such as hand sanitizers and environmental disinfectants.

Health authorities in various provinces of mainland China have officially recommended the use of herbal formulas to control the spread of COVID-19 in the general population. The main functions of these herbal formulas are to strengthen qi, expel external pathogens, disperse wind, and discharge heat. To this end, a total of 54 herbs have been listed, and PLE was the sixth most common extract in all formulas [16] . However, the exact role of PLE in such herbal formulations when used for directly targeting the virus remains unknown. The TCM Huoxiang Zhengqi capsules/Shui contain PLE and other herbs have been administered to dissipate cold and eliminate dampness. Few studies have described the use of these capsules to treat patients with COVID-19 during the medical observation period [17] [18] [19] . A clinical trial of Huoxiang Zhengqi capsules combined with Western medicines for treating patients with COVID-19 reported an improved therapeutic efficacy [20] . As PLE is a component of this formulation, it might be responsible for its anti-SARS-CoV-2 activity. We tested PLE derived from different batches and commercial suppliers and found that all of them displayed J o u r n a l P r e -p r o o f a similar anti-SARS-CoV-2 activity. Taken together, these findings clearly indicate that all of these formulations contain the same pharmacologically active principle(s) and attempts to identify and quantify them are currently ongoing.

Dramatic relative changes in cytokine levels have been observed in patients with severe COVID-19 [5] [6] [7] [8] . The occurrence of a hyperinflammatory state and the accumulation of monocytes/macrophages and neutrophils in lung tissues are typical features of severe disease [6] . In this context, anti-inflammatory inhibitors such as IL-1 and IL-6 blockers can be therapeutically useful [21] . Expectedly, we observed elevated levels of different 

The analytical methods and all study materials will be made available upon publication of the study. The original data set can be obtained from the corresponding author upon reasonable request.

Not applicable.

The authors declare they have no actual or potential competing financial interests. For each condition, the ratio of spike-positive cells was calculated in two independent experiments from >200 cells in randomly selected fields. *p < 0.05, **p < 0.01, and ***p<0.005. b. "-" indicates no activity or no cytotoxicity; "+" indicates protection or cytotoxicity. 

Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

editor Fields Virology

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Remdesivir for severe covid-19: a clinical practice guideline

Phytochemical and Pharmacological Investigations of Perilla frutescens

SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East

Daphne Genkwa sieb. Et zucc. Water-soluble extracts act on enterovirus 71 by inhibiting viral entry

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method

SynergyFinder: a web application for analyzing drug combination dose-response matrix data

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs

Application of Integrative Therapy Protocols for Treatment of Coronavirus Disease 2019 (COVID-19)

Notice on the issuance of guidelines of diagnosis and treatment for 2019

Compilation of drug information for the diagnosis and treatment of COVID-19 (version 1)

Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial

Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?

Role of combination antiviral therapy in pandemic influenza and stockpiling implications

Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial

The authors are grateful to Scintica Instrumentation Inc. for the kind gift of the CytoSMART